Bellidifolin Inhibits SRY-Related High Mobility Group-Box Gene 9 to Block TGF-β Signalling Activation to Ameliorate Myocardial Fibrosis

Figure 1

BEL did not affect HCF cells viability. HCFs were administered with different doses of BEL (3.125, 6.25, 12.5, 25, 50, and 100 μM) for 24 h, and a CCK-8 assay was applied to investigate the cell viability.